EGFR and breast cancer: While EGFR inhibitors have shown limited effects in patients that were not pre-selected according to molecular subtype [72,73], other reports suggested that EGFR targeting might be particularly efficient in the basal/squamous cell carcinoma-like BC subtype [57].